Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea

  • Younghee Jung1,
  • Myung Jin Lee3,
  • Hye-Yun Sin1,
  • Nak-Hyun Kim3,
  • Jeong-Hwan Hwang3,
  • Jinyong Park3,
  • Pyoeng Gyun Choe3, 5,
  • Wan Beom Park3, 5,
  • Eu Suk Kim1, 5,
  • Sang-Won Park5,
  • Kyoung Un Park2, 5,
  • Hong Bin Kim1, 5,
  • Nam-Joong Kim3, 5,
  • Eui-Chong Kim4, 5,
  • Kyoung-Ho Song1, 5Email author and
  • Myoung-don Oh3, 5
BMC Infectious Diseases201212:239

DOI: 10.1186/1471-2334-12-239

Received: 17 March 2012

Accepted: 27 September 2012

Published: 3 October 2012

Abstract

Background

Healthcare-associated (HCA) infection has emerged as a new epidemiological category. The aim of this study was to evaluate the impact of HCA infection on mortality in community-onset Klebsiella pneumoniae bloodstream infection (KpBSI).

Methods

We conducted a retrospective study in two tertiary-care hospitals over a 6-year period. All adult patients with KpBSI within 48 hours of admission were enrolled. We compared the clinical characteristics of HCA and community-acquired (CA) infection, and analyzed risk factors for mortality in patients with community-onset KpBSI.

Results

Of 553 patients with community-onset KpBSI, 313 (57%) were classified as HCA- KpBSI and 240 (43%) as CA-KpBSI. In patients with HCA-KpBSI, the severity of the underlying diseases was higher than in patients with CA-KpBSI. Overall the most common site of infection was the pancreatobiliary tract. Liver abscess was more common in CA-KpBSI, whereas peritonitis and primary bacteremia were more common in HCA-KpBSI. Isolates not susceptible to extended-spectrum cephalosporin were more common in HCA- KpBSI than in CA-KpBSI (9% [29/313] vs. 3% [8/240]; p = 0.006). Overall 30-day mortality rate was significantly higher in HCA-KpBSI than in CA-KpBSI (22% [70/313] vs. 11% [27/240]; p = 0.001). In multivariate analysis, high Charlson’s weighted index of co-morbidity, high Pitt bacteremia score, neutropenia, polymicrobial infection and inappropriate empirical antimicrobial therapy were significant risk factors for 30-day mortality.

Conclusions

HCA-KpBSI in community-onset KpBSI has distinctive characteristics and has a poorer prognosis than CA-KpBSI, but HCA infection was not an independent risk factor for 30-day mortality.

Keywords

Klebsiella pneumoniae Bacteremia Community-acquired infections Healthcare-associated Community-onset infection Epidemiology

Background

Within the last decade, the concept of healthcare-associated (HCA) infection has been introduced, and HCA infection has been described as an epidemiological category different from both community-acquired (CA) and nosocomial infection [1, 2]. Most importantly, mortality in HCA infection seems to be generally higher than that in CA infection, and similar to that in nosocomial infection [24]. However, there are conflicting results regarding whether HCA infection is an independent risk factor for mortality in bloodstream infection [1, 5]. A few pathogens have been studied in terms of HCA infection with S. aureus dominating the research, and these studies reported inconsistent data concerning the impact of HCA infection on mortality [613]. For gram-negative bacteria, the data on the impact of HCA infection on mortality were conflicting, as well [912].

Klebsiella pneumoniae is one of the most important gram-negative bacteria clinically, and K. pneumoniae bloodstream infection (KpBSI) has a mortality rate of about 20% [11, 1416]. Classically, KpBSI was simply classified into CA and nosocomial infections depending on bacteremia onset time: within 48 hours and after 48 hours of admission, respectively, and the different characteristics of CA-KpBSI versus nosocomial KpBSI have been well evaluated [11, 14, 15, 17, 18]. CA-KpBSI is usually associated with liver abscesses in patients with diabetes in East Asian countries, such as Korea and Taiwan [1922]. On the other hand, nosocomial KpBSI presents as primary bacteremia and/or pneumonia in patients with severe underlying diseases like malignancies. Thus, nosocomial infection has a higher mortality than CA infection [11, 14, 15, 17, 18]. However, there have been few studies of HCA-KpBSI [1113]. Therefore, we aimed to evaluate the impact of HCA infection on mortality and to compare the clinical characteristics of HCA and CA infection in patients with community-onset KpBSI.

Methods

Study setting and patients

We conducted a retrospective study of the medical records of the patients with KpBSI from January 2003 to December 2008 at Seoul National University Hospital (a 1,600-bed tertiary-care hospital, Seoul, Korea) and Seoul National University Bundang Hospital (a 900-bed tertiary-care hospital, Seongnam, Korea). All adult patients (≥18 year) who had KpBSI within 48 hours of admission were enrolled. When there were multiple KpBSI episodes only the first was included. We collected patient’s data on age, sex, underlying disease, site of infection, laboratory findings, microbiologic characteristics and treatment outcomes. To assess treatment outcomes we investigated 30-day mortality. This study was approved by the institutional review board of Seoul National University Hospital (IRB No. H-1010-062-336) and Seoul National University Bundang Hospital (IRB No. B-0910/086-004) according to the Helsinki Declaration.

Definitions

Community-onset KpBSI was defined as KpBSI occurring within 48 hours of admission. HCA-KpBSI was defined when a patient had one of the following medical histories: (1) intravenous therapy at home or in an outpatient clinic within the previous 30 days; (2) renal dialysis in a hospital or clinic within the previous 30 days; (3) hospitalization for 2 or more days within the previous 90 days; (4) residence in a nursing home or long-term care facility for 2 or more days [1]. Patients without any of these factors were classified as CA-KpBSI.

Biliary tract disease was defined when one or more complicated biliary stone was present, or there was a structural biliary abnormality due to benign or malignant disease. Chronic liver disease referred to chronic hepatitis and liver cirrhosis due to any cause. Charlson’s weighted index of co-morbidity and the Pitt bacteremia score were used to evaluate the severities of underlying disease and of acute illness, respectively [23, 24]. Shock was defined as a decrease in systolic blood pressure to 90mmHg or less, or a decrease of at least 40mmHg below baseline blood pressure despite adequate fluid resuscitation [25]. An absolute neutrophil count of less than 500/mL was defined as neutropenia. Polymicrobial infection was defined when any pathogen other than K. pneumoniae was isolated from blood culture at the same time as the K. pneumoniae, and the isolated pathogen also had clinical significance. Infection focus was assessed clinically by attending physician in accordance with site of isolation of K. pneumoniae.

The empirical antimicrobial therapy was defined as the initial antibiotic choice before the results of blood culture and antimicrobial susceptibility tests were available, and the definitive antimicrobial therapy was defined as the antibiotic choice after the report of microbiologic tests. K. pneumoniae which was not susceptible to either cefotaxime or ceftazidime was considered as ‘suspected extended-spectrum beta-lactamase (ESBL) producing K. pneumoniae’. Antimicrobial therapy was considered as ‘inappropriate’ when the treatment regimen did not include any antibiotic active in vitro. In addition 3rd generation cephalosporin monotherapy for ‘suspected ESBL-producing K. pneumoniae’ was considered ‘inappropriate’, regardless of the results of antibiotic susceptibility tests.

Microbiological analysis

All isolates were defined by BacT/ALERT FA and FN (bioMe´rieux, Durham, North Carolina). Antimicrobial susceptibility was identified by disk diffusion tests from 2003 to 2006, and by Microscan WalkAway-96 (Siemens Healthcare Diagnostics, Deerfield, Illinois) from 2007 to 2008, using the criteria of the Clinical and Laboratory Standards Institute (CLSI; formerly, National Committee for Clinical Laboratory Standards) guidelines. For the available ‘suspected ESBL-producing K. pneumoniae’ isolates, ESBL production was determined by the double disk synergy test according to the CLSI performance standards [26].

Statistical analysis

Student’s t-test was used to compare continuous variables and the χ2 test or Fisher’s exact test was used to compare categorical variables. To identify independent risk factors for 30-day mortality, a stepwise logistic regression model was used. Risk factors with a p value <0.10 in the univariate analysis for 30-day mortality were included in the initial model, and forward stepwise selection was performed to develop the final model. We included the Pitt bacteremia score instead of shock and, the Charlson’s weighted index of co-morbidity instead of underlying diseases to avoid data overlap in the multivariate analysis. p <0.05 was considered statistically significant. PASW for Windows (version 18 software package; SPSS Inc., Chicago, IL, USA) was used for all analyses.

Results

Demographics and underlying diseases

592 patients with community-onset KpBSI were identified in the 6-year period. Of these, 553 (93%) were analyzed, because 34 patients were lost to follow-up and medical record was not available in 5 patients. Of the 553 patients with community-onset KpBSI, 313 (57%) were classified as HCA-KpBSI and 240 (43%) as CA-KpBSI. The mean age of the 553 patients was 61 years (median: 63 years, range: 18–103), and 348 (63%) of the patients were male. Solid tumor was the most common underlying disease (238 patients, 43%). 145 (26%) patients had diabetes mellitus and 123 (22%) had chronic liver disease.

The demographics and underlying diseases of HCA-KpBSI and CA-KpBSI are listed in Table 1. Solid tumor (58% vs. 24%; p <0.001), hematologic malignancy (7% vs. 2%; p = 0.002) and chronic liver disease (27% vs. 16%; p = 0.003) were more common in HCA-KpBSI than in CA-KpBSI. Diabetes mellitus (31% vs. 23%; p = 0.031) was more common in CA-KpBSI than in HCA-KpBSI.
Table 1

Clinical characteristics of community-acquired and healthcare-associated infections in patients with community-onset Klebsiella pneumoniae bloodstream infection

 

CA-KpBSI

HCA-KpBSI

p

(n = 240)

(n = 313)

Age (years) (mean ±SD)

63.0 (±13.6)

60.3 (±12.9)

0.015

Male sex

142 (59.2)

206 (65.8)

0.124

Underlying disease

  Diabetes mellitus

74 (30.8)

71 (22.7)

0.031

  Chronic liver disease

39 (16.3)

84 (26.8)

0.003

  Biliary tract disease

42 (17.5)

43 (13.7)

0.224

  Chronic kidney disease

13 (5.4)

19 (6.1)

0.774

  Respiratory disease

18 (7.5)

21 (6.7)

0.719

  Solid tumor

58 (24.2)

180 (57.5)

<0.001

  Hematologic malignancy

4 (1.7)

23 (7.3)

0.002

  Solid organ transplantation

5 (2.1)

9 (2.9)

0.557

Charlson’s WIC (≥3)

47 (19.6)

141 (45.0)

<0.001

Primary infection site

  Urinary tract

31 (12.9)

34 (10.9)

0.457

  Peritoneum

11 (4.6)

46 (14.7)

<0.001

  Pancreatobiliary tract

82 (34.2)

102 (32.6)

0.696

  Liver

67 (27.9)

41 (13.1)

<0.001

  Lung

16 (6.7)

28 (8.9)

0.326

  Skin and soft tissue

4 (1.7)

8 (2.6)

0.477

  Bone

4 (1.7)

2 (0.6)

0.411

  Central nervous system

1 (0.4)

0 (0)

0.434

  Othersa

1 (0.4)

3 (1.0)

0.637

  Unknown

21 (8.8)

52 (16.6)

0.007

Metastatic infection

11 (4.6)

9 (2.9)

0.286

Endophthalmitis

5 (2.1)

3 (1.0)

0.303

Pitt bacteremia score (≥4)

36 (15.0)

56 (17.9)

0.366

Shock at presentation

55 (22.9)

101 (32.3)

0.015

Neutropenia at presentation

3 (1.3)

42 (13.4)

<0.001

Polymicrobial infection

34 (14.2)

47 (15.0)

0.780

Initial antimicrobial regimen

  Piperacillin-tazobactam

9 (3.8)

30 (9.6)

0.008

  Quinolone

23 (9.6)

18 (5.8)

0.088

  1st generation cephalosporin

2 (0.8)

0 (0)

0.188

  3rd generation cephalosporin

173 (72.1)

186 (59.4)

0.002

  Carbapenem

30 (12.5)

48 (15.3)

0.342

Inappropriate empirical antimicrobial therapy

14 (5.8)

26 (8.3)

0.266

Inappropriate definitive antimicrobial therapyb

7/223 (3.1)

7/278 (2.5)

0.675

30-day mortality

27 (11.3)

70 (22.4)

0.001

Data indicate no. (%) of patients. WIC, weighted index of co-morbidity; CA-KpBSI, community-acquired Klebsiella pneumoniae bloodstream infection; HCA-KpBSI, healthcare-associated Klebsiella pneumoniae bloodstream infection. a Others were one appendicitis, one pericarditis and two periodontitis. b 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).

Primary sites of infection and treatment outcomes

The pancreatobiliary tract was the most common site of infection (184 cases, 33%). Liver (108, 20%) and primary bacteremia (unknown focus) (73, 13%) were also frequent sites of infection. Initially 156 (28%) patients presented shock and 45 (8%) had neutropenia. 40 (7%) patients of the 553 patients were treated with inappropriate empirical antimicrobial therapy. After excluding 52 of the 553 patients (15 were transferred to other hospitals and 37 died before the culture results were reported), 14 of the remaining 501 patients (3%) were found to have been treated with inappropriate definitive antimicrobial therapy.

The primary sites of infection and treatment outcomes of HCA-KpBSI and CA-KpBSI are also compared in Table 1. Peritonitis (15% vs. 5%; p <0.001) and primary bacteremia (17% vs. 9%; p = 0.007) were more common in HCA-KpBSI than in CA-KpBSI. On the other hand, liver abscess (28% vs. 13%; p <0.001) was more frequent in CA-KpBSI than in HCA-KpBSI. Initial shock (32% vs. 23%; p = 0.015) and neutropenia (13% vs. 1%; p <0.001) were more common in HCA-KpBSI than in CA-KpBSI. The 30-day mortality of HCA-KpBSI was higher than that of CA-KpBSI (22% vs. 11%; p = 0.001).

Antimicrobial susceptibility

48 of the 553 isolates (9%) were not susceptible to ciprofloxacin and 37 isolates (7%) were not susceptible to either cefotaxime or ceftazidime. Of these 37 isolates, 27 were available for ESBL confirmatory tests and we performed the double disk synergy test on them. Eighteen were confirmed as producing ESBL. The antimicrobial susceptibilities of HCA-KpBSI and CA-KpBSI are compared in Table 2. A significantly higher proportion of the HCA-KpBSI than of the CA-KpBSI was resistant to tested antimicrobial agents other than imipenem and amikacin.
Table 2

Comparison of the antimicrobial susceptibility of community-acquired (CA) and healthcare-associated (HCA) Klebsiella pneumoniae bloodstream infection ( Kp BSI)

Antibiotics

CA-KpBSI (n = 240)

HCA-KpBSI (n = 313)

p

(Non-susceptible/T (%))

(Non-susceptible/T (%))

Ciprofloxacin

12/240 (5.0)

36/313 (11.5)

0.007

Extended-spectrum cephalosporin

8/240 (3.3)

29/313 (9.3)

0.006

  Cefotaxime

8/240 (3.3)

25/313 (8.0)

0.022

  Ceftazidime

6/240 (2.5)

25/313 (8.0)

0.005

ESBL-productiona

2/237 (0.8)

16/310 (5.2)

0.006

Piperacillin plus tazobactam

6/239 (2.5)

19/311 (6.1)

0.045

Aztreonam

5/175 (2.9)

26/253 (11.1)

0.004

Imipenem

1/240 (0.4)

1/313 (0.3)

1.000

Amikacin

7/240 (2.9)

17/313 (5.4)

0.150

Gentamicin

6/240 (2.5)

22/313 (7.0)

0.016

Tobramycin

7/177 (4.0)

26/253 (10.3)

0.015

Data indicate number of non-susceptible isolates/total number of tested isolates (%).

T, total number of tested isolates; ESBL, extended-spectrum beta-lactamase.

a 5 isolates among the CA-KpBSI were available for ESBL confirmatory tests and 14 among the HCA-KpBSI.

Risk factors for 30-day mortality

The results of the univariate analyses of risk factors for 30-day mortality are shown in Table 3. High Charlson’s weighted index of co-morbidity was a risk factor (odds ratio [OR], 2.86; 95% confidence interval [CI], 1.83-4.48) and, when we analyzed each underlying disease, solid tumor (OR, 3.32; 95% CI, 2.09-5.28) and hematologic malignancy (OR, 3.52; 95% CI, 1.58-7.84) also turned out to be significant risk factors. Infections of unknown origin (OR, 3.71; 95% CI, 2.17-6.34) and respiratory infections (OR, 3.38; 95% CI, 1.76-6.48) developed more frequently in non-survivors than in survivors. In contrast, liver abscess (OR, 0.11; 95% CI, 0.03-0.35) and pancreatobiliary infection (OR, 0.50; 95% CI, 0.30-0.84) were more common in survivors than in non-survivors. In addition, high Pitt bacteremia score (OR, 8.04; 95% CI, 4.87-13.28), neutropenia at initial presentation (OR, 4.48; 95% CI, 2.37-8.46), inappropriate empirical antimicrobial therapy (OR, 2.46; 95% CI, 1.22-4.96), polymicrobial infection (OR, 2.30; 95% CI, 1.34-3.94) and healthcare-associated infection (OR, 2.27; 95% CI, 1.41-3.68) were risk factors in univariate analyses. There was no significant difference in rates of antimicrobial resistance to ciprofloxacin (7.0% in survivors vs. 9.3% in non-survivors; p = 0.440) and extended-spectrum cephalosporin (6.4% in survivors vs. 8.2% in non-survivors; p = 0.499) between survivors and non-survivors.
Table 3

Risk factors for 30-day mortality among patients with community-onset Klebsiella pneumoniae bloodstream infection in univariate analysis

 

No. of survivors

No. of non-survivors

OR (95% CI)

p

(n = 456)

(n = 97)

Age (year) (mean ±SD)

61.1 (±13.5)

63.3 (±12.1)

 

0.146

Male sex

287 (62.9)

61 (62.9)

1.00 (0.63-1.57)

0.992

Underlying disease

    

  Diabetes mellitus

128 (28.1)

17 (17.5)

0.55 (0.31-0.96)

0.032

  Chronic liver disease

94 (20.6)

29 (29.9)

1.64 (1.01-2.68)

0.046

  Biliary tract disease

77 (16.9)

8 (8.2)

0.44 (0.21-0.95)

0.032

  Chronic kidney disease

28 (6.1)

4 (4.1)

0.66 (0.26-1.92)

0.440

  Respiratory disease

34 (7.5)

5 (5.2)

0.68 (0.26-1.77)

0.421

  Solid tumor

173 (37.9)

65 (67.0)

3.32 (2.09-5.28)

<0.001

  Hematologic malignancy

16 (3.5)

11 (11.3)

3.52 (1.58-7.84)

0.003

  Solid organ transplantation

13 (2.9)

1 (1.0)

0.36 (0.05-2.75)

0.482

Charlson's WIC (≥3)

135 (29.6)

53 (54.6)

2.86 (1.83-4.48)

<0.001

Primary infection site

    

  Urinary tract

58 (12.7)

7 (7.2)

0.53 (0.24-1.22)

0.126

  Peritoneum

42 (9.2)

15 (15.5)

1.80 (0.96-3.40)

0.066

  Pancreatobiliary tract

163 (35.7)

21 (21.6)

0.50 (0.30-0.84)

0.007

  Liver

105 (23.0)

3 (3.1)

0.11 (0.03-0.35)

<0.001

  Lung

27 (5.9)

17 (17.5)

3.38 (1.76-6.48)

<0.001

  Skin and soft tissue

8 (1.8)

4 (4.1)

2.41 (0.71-8.17)

0.239

  Bone

5 (1.1)

1 (1.0)

0.94 (0.11-8.13)

1.000

  Central nervous system

1 (0.2)

0 (0)

0.82 (0.79-0.86)

1.000

  Othersa

3 (0.7)

1 (1.0)

1.57 (0.16-15.28)

0.539

  Unknown

45 (9.9)

28 (28.9)

3.71 (2.17-6.34)

<0.001

Metastatic infection

18 (3.9)

2 (2.1)

0.51 (0.12-2.25)

0.551

Endophthalmitis

8 (1.8)

0 (0)

0.82 (0.79-0.86)

0.362

Pitt bacteremia score (≥4)

46 (10.1)

46 (47.4)

8.04 (4.87-13.28)

<0.001

Shock at presentation

97 (21.3)

59 (60.8)

5.75 (3.61-9.15)

<0.001

Neutropenia at presentation

25 (5.5)

20 (20.6)

4.48 (2.37-8.46)

<0.001

Healthcare-associated infection

243 (53.3)

70 (72.2)

2.27 (1.41-3.68)

0.001

Polymicrobial infection

57 (12.5)

24 (24.7)

2.30 (1.34-3.94)

0.002

Antimicrobial resistance

    

  non-susceptible to CIP

32 (7.0)

9 (9.3)

1.36 (0.63-2.94)

0.440

  non-susceptible to ESC

29 (6.4)

8 (8.2)

1.32 (0.59-2.99)

0.499

Inappropriate empirical antimicrobial therapy

27 (5.9)

13 (13.4)

2.46 (1.22-4.96)

0.010

Inappropriate definitive antimicrobial therapyb

12/446 (2.7)

2/55 (3.6)

1.37 (0.30-6.26)

0.659

Data indicate no. (%) of patients.

WIC, weighted index of co-morbidity; CIP, ciprofloxacin; ESC, extended-spectrum cephalosporin; OR, odds ratio; CI, confidence interval.

a Others were one appendicitis, one pericarditis and two periodontitis.

b 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).

From the multivariate logistic regression analysis, significant risk factors for 30-day mortality were high (≥3) Charlson’s weighted index of co-morbidity (adjust odds ratio [aOR], 3.23; 95% CI, 1.88-5.57), high (≥4) Pitt bacteremia score (aOR, 8.43; 95% CI, 4.70-15.11), neutropenia (aOR, 2.60; 95% CI, 1.24-5.48), polymicrobial infection (aOR, 2.36; 95% CI, 1.21-4.60) and inappropriate empirical antimicrobial therapy (aOR, 2.43; 95% CI, 1.07-5.52). Liver abscess (aOR, 0.17; 95% CI, 0.05-0.58) and pancreatobiliary tract infection (aOR, 0.42; 95% CI, 0.23-0.79) were found to be protective factors (Table 4). HCA infection was not an independent risk factor for mortality in multivariate analysis (aOR, 1.27; 95% CI, 0.70-2.30).
Table 4

Significant risk factors for 30-day mortality among community-onset Klebsiella pneumoniae bloodstream infection in multivariate analysis

 

No. of survivors (n = 456)

No. of non-survivors (n = 97)

Adjusted OR (95% CI)

p

Charlson's WIC (≥3)

135 (29.6)

53 (54.6)

3.23 (1.88-5.57)

<0.001

Pitt bacteremia score (≥4)

46 (10.1)

46 (47.4)

8.43 (4.70-15.11)

<0.001

Neutropenia

25 (5.5)

20 (20.6)

2.60 (1.24-5.48)

0.012

Polymicrobial infection

57 (12.5)

24 (24.7)

2.36 (1.21-4.60)

0.012

Pancreatobiliary infection

163 (35.7)

21 (21.6)

0.42 (0.23-0.79)

0.006

Liver abscess

105 (23.0)

3 (3.1)

0.17 (0.05-0.58)

0.038

Inappropriate empirical antimicrobial therapy

27 (5.9)

13 (13.4)

2.43 (1.07-5.52)

0.035

Data indicate no. (%) of patients.

WIC, weighted index of co-morbidity; OR, odds ratio; CI, confidence interval.

Discussion

In a previous study, we demonstrated that nosocomial KpBSI was different from CA- KpBSI [18]. However, the healthcare system has changed dramatically and this simple dichotomy is no longer appropriate for KpBSI in the current clinical setting. In this study we showed that HCA-KpBSI accounted for over 50% of community-onset KpBSI and HCA-KpBSI had different clinical characteristics from CA-KpBSI in terms of underlying disease, infection focus, antimicrobial susceptibility and treatment outcome. To our knowledge, this is the largest multicenter study comparing the clinical characteristics of HCA-KpBSI and CA-KpBSI [11, 12].

Cancer was the most common associated condition in HCA-KpBSI. In contrast, diabetes mellitus was the most common associated condition in CA-KpBSI. The distribution of underlying disease in HCA-KpBSI was similar to that in nosocomial KpBSI, except for the frequency of chronic liver disease. While we found previously that the frequency of this disease did not differ between CA-KpBSI and nosocomial KpBSI [18], it was more common in HCA-KpBSI than in CA-KpBSI (27% vs. 16%; p = 0.003) in the present study. The latter finding is similar to that of a study performed in Taiwan, although in the Taiwanese study the difference was not statistically significant (liver cirrhosis in HCA-KpBSI [14.0%] vs. CA- KpBSI [10.6%]; p = 0.339) [12].

The primary site of infection was identified in 87% of community-onset KpBSI. The most common source was the pancreatobiliary tract (33%), followed by liver abscess (20%). Liver abscess was more frequent in CA-KpBSI than in HCA-KpBSI. Compared to nosocomial KpBSI, in which liver abscess was very rare (0% to 2%) [11, 14, 18], HCA-KpBSI was quite frequently associated with liver abscess (13%). Peritonitis was fairly frequent (>10%), more so in HCA-KpBSI than in CA-KpBSI in our analysis; in contrast Wu et al. found only a few (<5%) of intra-abdominal infection and no difference in frequency between HCA-KpBSI and CA-KpBSI [12]. Our higher frequency of peritonitis may be due to the prevalence of chronic liver disease caused by hepatitis B or C virus in Korea, which increases the occurrence of spontaneous bacterial peritonitis [27, 28].

More of the HCA-KpBSI isolates than of the CA-KpBSI isolates were resistant to antimicrobial agents. Over 10% of the former were not susceptible to ciprofloxacin and 9% were not susceptible to one of the extended-spectrum cephalosporin. Although frequent antimicrobial resistance could affect the inadequacy of the initial choice of antimicrobial agent, there was no difference in rate of inappropriate empirical antimicrobial therapy between the HCA-KpBSI and the CA-KpBSI (6% vs. 8%; p = 0.266). This result could have arisen because in cases of healthcare-associated infection clinicians may have taken into account frequencies of antimicrobial resistance when selecting the initial antibiotic. Actually, fewer HCA-KpBSI than CA-KpBSI (6% vs. 10%; p = 0.088) were started on quinolones while more were started on piperacillin-tazobactam (Table 1).

Regarding empirical treatment, the proportion of patients treated inappropriately (7.2% of total patients) was much lower than was observed in other studies, which showed that over 20% of patients were treated inappropriately [9, 29, 30]. This discrepancy might have been the result of differences in the definition of ‘appropriate empirical treatment’, because the definition we used was less strict than those in other studies [3133]. In addition, broad-spectrum antimicrobial agents, such as 3rd generation cephalosporins or carbapenems, were frequently used empirically in our study (84.6% in CA infection, 74.7% in HCA infection). Considering that only 3.3% of organisms in CA infection and 9.3% of organisms in HCA infection were non-susceptible to extended-spectrum cephalosporins, the use of broad-spectrum antimicrobial agents also might have influenced the lower proportion of patients with treated inappropriately. However, other East Asian studies of K. pneumoniae bacteremia also demonstrated a similar proportion of patients treated with inappropriate empirical therapy [12, 14, 18].

There was a significant difference of 30-day mortality rate between HCA-KpBSI and CA-KpBSI in this study (22% vs. 11%; p = 0.001). High Charlson’s weighted index of co-morbidity (≥3), high Pitt bacteremia score (≥4), neutropenia, polymicrobial infection and inappropriate empirical antimicrobial therapy were found to be independent risk factors for mortality. However, HCA infection itself was not a significant risk factor for 30-day mortality in multivariate analysis. This finding is consistent with the recent report from Taiwan and a bloodstream infection study dealing with gram-negative bacteria [9, 12]. There are several explanations for this result. First, in our study, underlying disease and acute illness, which are classical risk factors for outcome of infectious disease, may have been so severe as to have attenuated the effect of HCA infection on mortality [23, 24, 34]. Second, whether the infection focus was removable, and was or was not removed, may have affected mortality more than whether the infection was HCA or not [35]. Liver abscess and pancreatobiliary infection can be classified as infections with removable foci, as opposed to pneumonia or primary bacteremia. In our study, percutaneous or internal drainage was performed in cases of liver abscess and obstructive pancreatobiliary infection, and these kinds of infection were found to be independent protective factors for mortality, as in the previous studies [11, 14, 18]. Third, as indicated by Friedman et al., the definition of HCA infection which we used in this study may have been excessively broad since the definition was based on the U.S. medical system [1]. Unlike the U.S., South Korea has started a national health insurance system in 1977 and extended it nationwide in 1982. Consequently, there is a tendency for more people to access the medical system and be classified as HCA infection in Korea. Such national differences in healthcare systems could complicate the unambiguous identification of patients with HCA infections so as to be able to evaluate the actual effect of HCA infection on mortality. Therefore we need further studies using a more accurate and consistent definition of HCA infection that accords better with variations in clinical practice.

Our study had several limitations. First, there was a potential bias because it was performed retrospectively. Second, it was conducted in tertiary-care and university-affiliated hospitals and there was a large proportion of cancer patients in both the CA-KpBSI and HCA-KpBSI groups. Hence, we cannot extrapolate our result to community-based institutions. Third, we did not evaluate the ‘attributable’ mortality due to KpBSI, so that some of the deaths in our study may not have been related to KpBSI. However, efforts to designate outcomes as ‘attributable’ to infection are often subjective and inconsistent. We therefore employed an unambiguous definition, namely 30-day mortality rate, for evaluating treatment outcomes. Fourth, because we did not review the patients’ previous exposure to antimicrobial agents, we could not determine the influence of that factor on the acquiring resistant organisms and treatment outcome. Additionally, we did not collect data on the variation of antimicrobial therapy, such as duration or dosage; therefore, we could not take into account these issues, which could affect the analysis of risk factors for mortality. However, upon examining the mortality rate in other studies, our data are comparable; therefore, the regimen and duration of therapy we used were also likely to be similar to others [12, 14].

What clinicians actually want to know is that HCA infection needs a specific work-up process or treatment. Accordingly, our study can provide useful information. First, we could see the difference of infection focus according to the epidemiological category more clearly by separating HCA infection and CA infection in comparison to our previous report [18]. Peritonitis is more commonly associated with HCA infection than with CA infection in the present study, while the frequency of peritonitis in CA infection was relatively high (20.4%) and was not different from that observed in nosocomial infection in the previous study [18]. However, when we classified more precisely we could see that peritonitis occurred in much lower frequency in true CA infection. In addition, we could identify the infection focus of all but 8.8% of the patients with true CA infection (in previously defined CA infection, 25.7% patients were unidentified for infection focus) [18]. Second, comparing the resistance rate to antimicrobial agents in HCA infection with CA infection can help clinicians choose an initial antimicrobial agent in treating patients of each subset, which means not only should we consider broad-spectrum antimicrobial agents in HCA infection but also that we may not need to start broad-spectrum antimicrobial agents, such as extended-spectrum cephalosporins or carbapenems, in CA infection. Based on our data, quinolone can be a drug of choice in treating true CA-KpBSI. Finally, even though we showed many differences between HCA infection and CA infection, we did not find HCA infection to be an independent risk factor for mortality in KpBSI, which confirmed that the already known risk factors for mortality (severity of underlying disease, inadequate empirical therapy and severity of acute illness) are more important predictors of mortality in KpBSI [12, 14].

Conclusion

HCA-KpBSI represented over half of community-onset KpBSI and had different characteristics from CA-KpBSI. In HCA-KpBSI, underlying diseases were more severe, primary bacteremia and peritonitis were more common and resistance to antimicrobials was more frequent than in CA-KpBSI. HCA-KpBSI had higher 30-day mortality than CA-KpBSI, but HCA infection was not an independent risk factor for 30-day mortality. In present-day clinical circumstances, HCA-KpBSI should be identified as a distinctive category and be approached in a different way from CA-KpBSI.

Declarations

Acknowledgement

This study was supported by grant No. 11-2009-012 from the Seoul National University Bundang Hospital Research Fund. This study was presented in part at the 49th annual meeting of the Infectious Diseases Society of America, Boston, 2011 (Abstract number 990).

Authors’ Affiliations

(1)
Department of Internal Medicine, Seoul National University Bundang Hospital
(2)
Department of Laboratory Medicine, Seoul National University Bundang Hospital
(3)
Department of Internal Medicine, Seoul National University Hospital
(4)
Department of Laboratory Medicine, Seoul National University Hospital
(5)
Seoul National University College of Medicine

References

  1. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, et al: Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002, 137: 791-797.View ArticlePubMedGoogle Scholar
  2. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH: Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med. 2006, 34: 2588-2595.View ArticlePubMedGoogle Scholar
  3. Valles J, Calbo E, Anoro E, Fontanals D, Xercavins M, Espejo E, Serrate G, Freixas N, Morera MA, Font B, et al: Bloodstream infections in adults: importance of healthcare-associated infections. J Infect. 2008, 56: 27-34.View ArticlePubMedGoogle Scholar
  4. Kollef MH, Zilberberg MD, Shorr AF, Vo L, Schein J, Micek ST, Kim M: Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect. 2011, 62: 130-135.View ArticlePubMedGoogle Scholar
  5. Lenz R, Leal JR, Church DL, Gregson DB, Ross T, Laupland KB: The distinct category of healthcare associated bloodstream infections. BMC Infect Dis. 2012, 12: 85-View ArticlePubMedPubMed CentralGoogle Scholar
  6. Liao CH, Chen SY, Chang SC, Hsueh PR, Hung CC, Chen YC: Characteristics of community-acquired and health care-associated Staphylococcus aureus bacteremia in patients treated at the emergency department of a teaching hospital. Diagn Microbiol Infect Dis. 2005, 53: 85-92.View ArticlePubMedGoogle Scholar
  7. Lesens O, Hansmann Y, Brannigan E, Hopkins S, Meyer P, O'Connel B, Prevost G, Bergin C, Christmann D: Healthcare-associated Staphylococcus aureus bacteremia and the risk for methicillin resistance: is the Centers for Disease Control and Prevention definition for community-acquired bacteremia still appropriate?. Infect Control Hosp Epidemiol. 2005, 26: 204-209.View ArticlePubMedGoogle Scholar
  8. Pastagia M, Kleinman LC, de la Cruz EG L, Jenkins SG: Predicting risk for death from MRSA bacteremia (1). Emerg Infect Dis. 2012, 18: 1072-1080.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Marschall J, Fraser VJ, Doherty J, Warren DK: Between Community and Hospital: Healthcare-Associated Gram-Negative Bacteremia among Hospitalized Patients. Infect Control Hosp Epidemiol. 2009, 30: 1050-1056.View ArticlePubMedGoogle Scholar
  10. Cheong HS, Kang CI, Kwon KT, Heo ST, Wi YM, Kim ES, Lee JS, Ko KS, Chung DR, Lee NY, et al: Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrol Chemother. 2007, 60: 1355-1360.View ArticleGoogle Scholar
  11. Meatherall BL, Gregson D, Ross T, Pitout JD, Laupland KB: Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med. 2009, 122: 866-873.View ArticlePubMedGoogle Scholar
  12. Wu HS, Wang FD, Tseng CP, Wu TH, Lin YT, Fung CP: Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan. J Infect. 2012, 64: 162-168.View ArticlePubMedGoogle Scholar
  13. Sun HY, Chen SY, Chang SC, Pan SC, Su CP, Chen YC: Community-onset Escherichia coli and Klebsiella pneumoniae bacteremia: influence of health care exposure on antimicrobial susceptibility. Diagn Microbiol Infect Dis. 2006, 55: 135-141.View ArticlePubMedGoogle Scholar
  14. Tsay RW, Siu LK, Fung CP, Chang FY: Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med. 2002, 162: 1021-1027.View ArticlePubMedGoogle Scholar
  15. Yinnon AM, Butnaru A, Raveh D, Jerassy Z, Rudensky B: Klebsiella bacteraemia: community versus nosocomial infection. QJM. 1996, 89: 933-941.View ArticlePubMedGoogle Scholar
  16. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, et al: International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004, 140: 26-32.View ArticlePubMedGoogle Scholar
  17. Watanakunakorn C, Jura J: Klebsiella bacteremia: a review of 196 episodes during a decade (1980–1989). Scand J Infect Dis. 1991, 23: 399-405.View ArticlePubMedGoogle Scholar
  18. Kang CI, Kim SH, Bang JW, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW: Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci. 2006, 21: 816-822.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wann SR, Lin HH: Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 1998, 26: 1434-1438.View ArticlePubMedGoogle Scholar
  20. Chung DR, Lee SS, Lee HR, Kim HB, Choi HJ, Eom JS, Kim JS, Choi YH, Lee JS, Chung MH, et al: Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect. 2007, 54: 578-583.View ArticlePubMedGoogle Scholar
  21. Fung CP, Chang FY, Lee SC, Hu BS, Kuo BI, Liu CY, Ho M, Siu LK: A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important factor for complicated endophthalmitis?. Gut. 2002, 50: 420-424.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Kim JK, Chung DR, Wie SH, Yoo JH, Park SW: Risk factor analysis of invasive liver abscess caused by the K1 serotype Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2009, 28: 109-111.View ArticlePubMedGoogle Scholar
  23. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-383.View ArticlePubMedGoogle Scholar
  24. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991, 115: 585-590.View ArticlePubMedGoogle Scholar
  25. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008, 36: 296-327.View ArticlePubMedGoogle Scholar
  26. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing. Seventh informational supplement. CLSI document M100-S17. 2007, Wayne: CLSIGoogle Scholar
  27. Chae HB, Kim JH, Kim JK, Yim HJ: Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol. 2009, 15 (Suppl 6): S13-S24.View ArticlePubMedGoogle Scholar
  28. Shin HR: Epidemiology of hepatitis C virus in Korea. Intervirology. 2006, 49: 18-22.View ArticlePubMedGoogle Scholar
  29. McDonald JR, Friedman ND, Stout JE, Sexton DJ, Kaye KS: Risk factors for ineffective therapy in patients with bloodstream infection. Arch Intern Med. 2005, 165: 308-313.View ArticlePubMedGoogle Scholar
  30. Son JS, Song JH, Ko KS, Yeom JS, Ki HK, Kim SW, Chang HH, Ryu SY, Kim YS, Jung SI, et al: Bloodstream infections and clinical significance of healthcare-associated bacteremia: a multicenter surveillance study in Korean hospitals. J Korean Med Sci. 2010, 25: 992-998.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000, 118: 146-155.View ArticlePubMedGoogle Scholar
  32. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM: The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect. 2003, 9: 412-418.View ArticlePubMedGoogle Scholar
  33. Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, Lee HS, Kim NJ, Choe KW: Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producingEscherichia coliandKlebsiellaspecies: a retrospective matched case–control study. BMC Infect Dis. 2009, 9: 41-View ArticlePubMedPubMed CentralGoogle Scholar
  34. Oltean S, TT D, Bondor C, Slavcovici A, Cismaru C, Lupse M, Muntean M, Jianu C, Marcu C, Oltean M: Charlson's weighted index of comorbidities is useful in assessing the risk of death in septic patients. J Crit Care. 2012, 27: 370-375.View ArticlePubMedGoogle Scholar
  35. Kim SH, Park WB, Lee KD, Kang CI, Kim HB, Oh MD, Kim EC, Choe KW: Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis. 2003, 37: 794-799.View ArticlePubMedGoogle Scholar
  36. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/12/239/prepub

Copyright

© Jung et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.